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Background: Exhaled nitric oxide provides a convenient, non-invasive insight into airway
inflammation. However it is suppressed by current smoking, reducing its potential as an
endpoint in studies of smokers with asthma, a group with increased symptoms and poor clinical
responses to corticosteroids. We examined extended nitric oxide analysis as some derived vari-
ables are thought to be unaffected. Therefore this approach could reveal hidden inflammation
and enable its use as an exploratory endpoint in this group.
Methods: Smokers (nZ 22) and never smokers (nZ 21) with asthma performed exhaled nitric
oxide measurements and spirometry before and after two weeks of oral dexamethasone (6 mg/
1.74 m2/day). Linear and non-linear nitric oxide analysis was performed to derive estimates for
alveolar nitric oxide (Calv) and nitric oxide flux (J
0
aw) for each subject.
Results: FENO50 was significantly lower in smokers with asthma and did not change significantly
in response to dexamethasone. Calv derived by linear modelling was lower in smokers with
asthma and did not change significantly in response in either group. J0aw was substantially
lower in smokers with asthma (smokers (median (IQR)); 573 pl/s (217, 734), non-smoker;
1535 pl/s (785, 3496), p Z 0.001) and was reduced in both groups following dexamethasone
(non-smokers change (mean (95% CI)); 743.3 pl/s (1710, 163), p Z 0.005, smokers;
293 pl/s (572, 60), p Z 0.016). Correction for axial flow did not substantially change
the derived results.)141 211 1673; fax: þ44 (0)141 211 3464.
ow.ac.uk (M. Spears).
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1824 M. Spears et al.Conclusions: Bronchial NO flux appears to be sensitive to oral dexamethasone and may provide
a useful exploratory endpoint for the analysis of novel anti-inflammatory therapies in smokers
with asthma.
ª 2011 Elsevier Ltd. All rights reserved.Introduction
Non-invasive assessment of airway inflammation, through
the measurement of exhaled nitric oxide at a flow rate of
50 ml/s (FENO50), is a useful exploratory endpoint as it
provides a rapid and sensitive assessment of airway
inflammation.1 However, current cigarette smoking reduces
FENO50
2 diminishing its usefulness, both for the assessment
of airway inflammation and as an exploratory endpoint in
clinical trials in smokers with asthma. This is unfortunate as
smokers with asthma demonstrate reduced responses to
both inhaled3,4 and oral5,6 corticosteroids and new treat-
ments are urgently required for this sub-group of asthma. A
simple non-invasive marker of inflammation that demon-
strated a rapid improvement with treatment would facili-
tate the conduct of short term exploratory clinical trials
and hence drug development for this group.
An alternative approach involves examination of exhaled
nitric oxide parameters using multiple exhalation flow
rates.7,8 This method employs mathematical modelling
based on the assumption that the lungs can be divided into
two compartments corresponding to Weibel generations
1e16 and 17-23 (thereby reflecting the conducting and
small airways/alveoli respectively).7 The result derived for
the small airways is termed alveolar nitric oxide (Calv) and
the conducting airways nitric oxide flux (J0aw; the rate of
radial transport of nitric oxide across the airway into the
exhaled air).7e11
Unlike FENO50, active smoking does not reduce Calv in
either normal subjects12,13 or in smokers and ex-smokers
with COPD.14,15 Increased Calv levels have been observed
in poorly controlled non-smokers with asthma and Calv also
normalises with oral corticosteroids in these subjects.16,17
Therefore measurement of Calv and J0aw may provide
useful exploratory endpoints in the assessment of airway
inflammation and response to novel anti-inflammatory
therapies. This study aimed to test the hypotheses that
Calv is raised and J
0
aw is reduced in smokers with asthma
compared to non-smokers with asthma, reflecting their
worse asthma control and that short term treatment with
oral corticosteroids would normalise alveolar nitric oxide.
Methods
Subjects
Smokers and non-smokers with mild to moderate asthma18
prescribed a maximum of 2000 mcg beclometasone (or
equivalent) were recruited. Smokers with asthma were
current smokers (5 cigarettes/day & 5 pack year
history). Non-smokers with asthma were never smokers. All
subjects demonstrated either FEV1 bronchodilator response
of 12% (and 200 ml), peak expiratory flow (PEF) lability(>20% diurnal change for three days over one week) or
a positive methacholine challenge test (drop in FEV1  20%
at a concentration of  8 mg/ml) and provided written
informed consent. The study was approved by West Glas-
gow Ethics Committee.
Study design
The study comprised a maximum of 4 visits. Visit one
recorded lung function and demographics. If bronchodilator
response was absent, PEF lability was assessed at a further
visit and if absent methacholine testing was performed.
Subjects meeting entry criteria were invited to two further
visits to assess corticosteroid response. These included
exhaled nitric oxide measurement, spirometry, assessment
of asthma control via asthma control questionnaire (ACQ)
score19 and sputum induction. Open label dexamethasone
was administered at a daily dose of 6 mg/1.74 m2 for two
weeks. The post corticosteroid visit was performed at the
same time of day (þ/2 h) as the baseline visit. Subjects
were asked to refrain from smoking, eating and caffeine
containing drinks within three hours of testing. Cortico-
steroid compliance was confirmed by suppression of blood
cortisol (<50 nmol/l). Smoking status was confirmed by
urine cotinine20 and exhaled carbon monoxide.
Measurements
Spirometric and methacholine testing complied with rele-
vant guidelines.21,22 Sputum induction was performed as
previously described.23 Nitric oxide measurements (50 ml/
s) complied with consensus guidelines1 and were also per-
formed at multiple flow rates (30, 50, 100, 150, 200, 250
and 300 ml/s) to allow calculation of endpoints using non-
linear and linear regression. The measurements were per-
formed using a Niox-Flex analyzer with built-in Flex-Flow
programme, automatic flow regulator and nitric oxide
scrubber (Aerocrine AB, Sundbybergsva¨gen 9, SE-171 73
Solna, Sweden). The exhalation time for each flow rate
was; 10 s for 30 ml/s and 50 ml/s, 6 s for 100, 150, 200, 250
and 300 ml/s. Three readings were obtained for each flow
rate. The exhaled nitric oxide concentration, elimination
rate of nitric oxide (amount of NO absorbed from the airway
wall into the airstream) and exhalation flow rate were
plotted followed by linear or non-linear fitting to the data.
Exhaled nitric oxide linear and non-linear modelling was
performed according to published methodology.7,9,11 Illus-
trative examples are provided in Fig. 1 & Fig. 2. Linear
modelling was performed using VNO results from 100, 200
and 300 ml/s flow rates. Data from subjects which
produced a negative value for Calv were discarded. A
sensitivity analysis was performed to assess the depen-
dence of the results on this analysis strategy; the clinical
features of those omitted from and retained in the analysis
Figure 1 Illustrative example of linear regression plot. Line
represents linear regression through the data points. The slope
of the derived line provides the alveolar nitric oxide concen-
tration and the y-intercept airway wall flux. VNO; elimination
rate of exhaled nitric oxide, pl/sec; picolitres per second, ml/
sec; millilitres per second.
Table 1 Demographics and baseline clinical characteristics.
Smokers
(n Z 22)
Non-Smokers
(n Z 21)
Age (yrs) 46.6 (6.7) 42.5 (10.0)
Sex (F:M) 12:10 11:10
Asthma Duration (yrs) 22.1 (15.9) 28.6 (15.0)
Pack yrs 27.6 (15.7)
Inhaled corticosteroid 1046 * (611) 679 (419)
Nitric oxide flux in smokers with asthma 1825were compared. Non-linear regression was performed with
the restriction of positive boundaries for all parameters.
Correction for axial diffusion was also performed for the
linear results using the method developed by Condorelli
et al.24
Statistical analysis
Standard power calculations were not possible given the
lack of research focused on smokers with asthma in this
area. However we were informed by previous research
examining lung function responses to oral corticosteroids in
smokers with asthma.5This resulted in the estimate that 22
subjects were required to provide 80% power to demon-
strate a difference of 336 ml in FEV1 response between
smokers and non-smokers with asthma and to allow for
a 10% drop-out rate. Levels were compared between groups
using the two sample t-test or ManneWhitney test and
within groups using the paired t-test or Wilcoxon signed
rank test as appropriate and subsequently presented as
either median (interquartile range [IQR]) or mean (95% CI).
Correlations were determined using the Spearman rank
correlation co-efficient (rs). A 5% significance level was
applied throughout. Analysis and modelling was performed
using SAS v 9.2 for Windows (SAS Institute Inc., NC, USA).Figure 2 Example plot of exhaled nitric oxide concentration
against exhalation flow rate. Line represents non-linear
regression through the data points. FENO; exhaled nitric oxide
concentration, ppb; parts per billion, ml/sec; millilitres per
second.Results
Baseline comparisons
The subjects were well matched at baseline except for
a higher ACQ score and inhaled corticosteroid dose and
smaller bronchodilator response in the smokers with
asthma (Table 1). Sputum eosinophil and neutrophil
proportions were normal25 and equivalent in both groups.
Clinical response to oral dexamethasone
22 smokers and 21 non-smokers with asthma completed the
pre dexamethasone visit and 20 smokers and 17 non-
smokers completed the dexamethasone trial. Non-smokers
with asthma had a substantial lung function response to
oral dexamethasone in contrast to smokers with asthma
(non-smokers with asthma; mean FEV1 change 173 ml (95%
CI 10, 336), pZ 0.039, smokers with asthma; 32 ml (115,
178), p Z 0.657). No clinically or statistically significant
improvement in ACQ score was evident when within groups
changes were compared (smokers median (IQR) ACQ
change; 0.15 (0.9, 0.3), non-smokers; 0.20 (0.7,
0.0), p Z 0.690).
Exhaled nitric oxide-FENO50
FENO50 values were significantly reduced in smokers with
asthma compared to non-smokers at baseline (p < 0.001)
and on completion of the oral corticosteroid trial (Table 2).
FENO50 was significantly reduced in non-smokers with
asthma in response to oral dexamethasone (median absolute(mcg/day)
ACQ Score (0e6) 2.2 * (0.9) 1.5 (0.8)
Pre BD FEV1 (% predicted) 73.6 (18.5) 73.3 (15.3)
Pre BD FEV1/FVC 68.1 (12.1) 65.9 (9.9)
FEV1% BD response 15.1 * (8.5) 23.3 (15.9)
Sputum Total cell count
(106)
6.1 (6.5) 7.1 (14.8)
Sputum Eosinophils
Median (IQR)
(%) 0.4 (0.0, 1.0) 0.3 (0.0, 2.0)
(104) 2.0 (0.0, 4.0) 1.0 (0.0, 7.0)
Sputum Neutrophils
Median (IQR)
(%) 34 (24, 56) 24 (11, 41)
(104) 125 (77, 240) 107 (39, 178)
Data presented as mean (SD) unless specified. *; p < 0.05.
Abbreviations; SD; standard deviation, Yrs; years, mcg; micro-
gram, ACQ; Asthma Control Questionnaire score (range, 0 to 6,
with higher scores indicating worse asthma control), BD; bron-
chodilator, FEV1; forced expiratory volume in 1 s, FVC; forced
vital capacity, IQR; interquartile range.
Table 2 Baseline and post oral dexamethasone exhaled nitric oxide results.
Smokers Non-smokers
Pre steroid Post steroid Pre steroid Post steroid
FENO50 (ppb) 11.1
z (3.6, 13.5) 6.1 y (3.3, 8.1) 32.8 (17.7, 73.2) 12.4 (10.1, 22.0)
Calv (ppb) Linear 1.42 * (0.4, 2.0) 1.79 (0.7, 2.4) 2.45 (1.1, 3.5) 1.89 (1.4, 2.9)
Non-linear 1.39 (0.0, 2.0) 0.97 (0.0, 2.0) 0.78 (0.0, 1.7) 1.25 (0.4, 2.1)
J0aw (pl/s) Linear 573
y (217, 734) 148 z (65, 458) 1535 (785, 3496) 577 (457, 1362)
Non-linear 697 y (322, 1205) 336 y (279, 732) 2088 (1093, 5034) 677 (608, 1132)
FENO50; exhaled nitric oxide concentration at 50 ml/s, ppb; parts per billion, Calv; alveolar nitric oxide, J
0
aw; nitric oxide flux, pl/s;
picolitres per second. Data presented as median (IQR). *; p < 0.05,y; p < 0.01, z, p < 0.001.
1826 M. Spears et al.change; 20.6 ppb (IQR 53.5, 7.8), p < 0.001, % change;
55.9% (68.9, 26.2), p < 0.001). However smokers with
asthma did not demonstrate a significant reduction in FENO50
in response to corticosteroid treatment, whether examined
as absolute (1.9 ppb (5.7, 0.7), p Z 0.098) or % FENO50
change from baseline (26.5% (44.2, 23.0), pZ 0.550).
No significant relationships were evident between change
in ACQ score and % change in FENO50 in either non-smokers
(rsZ 0.38 (95% CI 0.12, 0.73), pZ 0.128) or smokers with
asthma (rsZ 0.01 (0.49, 0.47), pZ 0.956).Extended nitric oxide analysis
Linear modelling resulted in negative values for Calv in some
subjects. Given concern over the lack of relationship with
physiological nitric oxide production, the results for these
subjects were not incorporated in the formal comparisons.
Sensitivity analyses including these subjects gave qualita-
tively similar results to those reported here, showing that
our findings are not due to the exclusion those with nega-
tive Calv values. The baseline demographics for those
removed and the remainder is displayed in Table 3 and the
results including subjects with negative values for Calv are
displayed in Table 4. The subjects with negative values forTable 3 Demographics and baseline characteristics of subjects
Negative
Age (yrs) 44.0 (6.
Sex (m:f) 3:2
Asthma Duration (yrs) 18.2 (19
Inhaled steroid (mcg/day) 1080 (52
Smokers (% of group) 80 *
ACQ Score (0e6) 2.2 (0.
FENO50 (ppb) 23.0 (36
Pre BD FEV1 (% predicted) 55.8 * (13
Pre BD FEV1/FVC (%) 55.1 * (9.
Total cell count (106) 6.3 (3.
Eosinophils (%) Median (IQR) 1.0 (0.
Eosinophils (104) Median (IQR) 4.0 (0.
Neutrophils (%) Median (IQR) 21.0 (16
Neutrophils (104) Median (IQR) 96.0 (73
Data presented as mean (SD) except where indicated. *; p < 0.05. Ab
ACQ; Asthma Control Questionnaire score (range, 0 to 6, with highe
oxide measured at flow rate of 50 ml/s, ppb; parts per billion, BD; b
vital capacity, IQR; interquartile range.alveolar NO were more likely to be smokers and had lower
FEV1 % predicted and FEV1/FVC.
Alveolar nitric oxide (Calv)
In contrast to our expectations, smokers with asthma had
lower Calv values at baseline when derived by linear
modelling (smokers with asthma Calv; 1.4 ppb (0.4, 2.0), non-
smokers with asthma Calv; 2.5 ppb (1.1, 3.5), p Z 0.026)
(Table 2). However no significant difference was evident
when non-linear modelling was employed. No difference was
evident when Calv post oral dexamethasone and change in
response to dexamethasone were compared. Adjustment for
axial flow did not appear to substantially change the results
for alveolar nitric oxide (CalvTMAD) both pre (smokers CalvTMAD;
1.8 ppb (IQR 1.1, 2.5), non-smokers CalvTMAD; 1.1 ppb (0.9,
2.1), p Z 0.220) and post oral dexamethasone (smokers
CalvTMAD; 1.6 ppb (0.7, 2.4), non-smokers CalvTMAD; 1.5 ppb
(0.7, 2.1), p Z 0.860).
Airway wall flux (J0aw)
Linear modelling
J0aw was significantly lower in smokers with asthma compared
to non-smokerswith asthma at baseline (smokers J0aw; 573 pl/
s (217, 734), non-smokers J0aw; 1535 pl/s (785, 3495),
p Z 0.002) (Fig. 3). As expected, non-smokers with asthmaincluded and excluded based on alveolar nitric oxide value.
Calv (n Z 5) Positive Calv (n Z 38)
6) 44.7 (8.9)
17:21
.6) 26.2 (15.1)
2) 838 (556)
47
7) 1.8 (0.9)
.0) 32.3 (37.5)
.4) 75.8 (16.0)
6) 68.6 (10.3)
5) 11.7 (15.1)
0, 2.8) 0.3 (0.0, 1.0)
0, 11.0) 1.0 (0.0, 4.0)
, 45) 26.0 (11, 52)
, 219) 103.0 (36, 162)
breviations; SD; standard deviation, Yrs; years, mcg; microgram,
r scores indicating worse asthma control), FENO50; exhaled nitric
ronchodilator, FEV1; forced expiratory volume in 1 s, FVC; forced
Table 4 Baseline and post oral dexamethasone results inclusive of subjects with negative values for alveolar nitric oxide (Calv)
by linear modeling.
Smokers Non-smokers
Pre steroid Post steroid Pre steroid Post steroid
Calv (ppb) 0.69 * (0.2, 1.9) 1.76 (0.7, 2.4) 2.19 (1.1, 3.4) 1.88 (0.8, 2.9)
J0aw (pl/s) 573
z (217, 734) 156 y (65, 612) 1564 (797, 3659) 545 (457, 870)
ppb; parts per billion, Calv; alveolar nitric oxide, J
0
aw; nitric oxide flux, pl/s; picolitres per second. Data presented as median (IQR). *;
p < 0.05,y; p < 0.01, z, p < 0.001.
Nitric oxide flux in smokers with asthma 1827demonstrated a large reduction in J0aw in response to oral
dexamethasone (743.3 pl/s (95% CI -1710, 163),
pZ0.005).However, smokerswithasthmaalsodemonstrated
a significant reduction (293 pl/s (572, 60), pZ 0.016).
Non-linear modelling
When derived by non-linear modelling, nitric oxide flux
(J0awnl) values were again significantly lower in smokers
with asthma (smokers J0awnl; 697 pl/s (IQR 323, 1205), non-
smokers J0awnl; 2088 pl/s (1093, 5034), p Z 0.002). Non-
smokers with asthma demonstrated a large and statisti-
cally significant reduction in response to oral dexametha-
sone (1363 pl/s (95% CI -3831, 725), p < 0.001) whilst
smokers with asthma demonstrated a tendency to a reduc-
tion (260 pl/s (492, 33), p Z 0.064).
Linear regression-TMAD modelling
Airway wall nitric oxide flux (JawTMAD) was significantly lower
in smokers with asthma pre (smokers JawTMAD 232 pl/s (63,
920), non-smokers JawTMAD; 1978 pl/s (1219, 2884), pZ 0.002)
and post dexamethasone (smokers JawTMAD; 315 pl/s (151,
461), non-smokers JawTMAD; 871 pl/s (755, 1562), pZ 0.001).
Smokers with asthma demonstrated a tendency to
a reduction in JawTMAD in response to dexamethasone
(173 pl/s (514, 1), p Z 0.098).Relationship between flux and FENO50
Given the close relationship that is known to exist between
Jaw and FENO50 and our demonstration of dissociation in theirFigure 3 Pre and post dexamethasone J0aw (derived by linear
modelling) in non-smokers and smokers with asthma.response to oral dexamethasone we sought to examine the
correlation between change in Jaw and FENO50. Confirming
previous reports we discovered a strong correlation between
Jaw and FENO50 in both non-smokers (rs Z 0.94 (95% CI 0.86,
0.98), p < 0.001) and smokers with asthma (rsZ 0.90 (0.75,
0.97), p < 0.001) at baseline. This relationship remained
strong when change in Jaw and FENO50 was examined in non-
smokers with asthma (rs Z 0.97 (0.92, 0.99), p < 0.001).
However when examined in smokers with asthma this
correlation, whilst still statistically significant, was obviously
weaker (rs Z 0.72 (0.36, 0.89), p < 0.001).
Relationship between flux and clinical
characteristics
No significant correlation was evident between change in
ACQ in response to oral dexamethasone and J0aw (non-
smokers with asthma; rs Z 0.28 (95% CI -0.22, 0.67),
p Z 0.263, smokers with asthma; rs Z 0.21 (0.30, 0.63),
p Z 0.415) and no significant correlation was evident
between baseline inhaled corticosteroid dose and J0aw
response to dexamethasone in non-smokers with asthma
(rs Z 0.33 (0.18, 0.70), p Z 0.192) but a tendency to
a correlation was evident between inhaled corticosteroid
dose at baseline and J0aw response to dexamethasone in
smokers with asthma (rs Z 0.43 (0.76, 0.06),
p Z 0.076).Discussion
Smokers with asthma display a reduced clinical response
to inhaled and oral corticosteroids26 associated with
a reduction in asthma control as reflected in their higher
ACQ scores27 and health care usage.28 New treatments in
development for corticosteroid resistant inflammation
may be useful in the management of this group. However
the reduced clinical responses of smokers with asthma to
corticosteroids, coupled to the cost and effort involved in
performing definitive clinical trials mean that short term
exploratory trials employing endpoints more applicable to
studies of non-smokers with asthma may not provide
sufficient insight into the efficacy of new therapies in this
group. An endpoint that detects early and subtle anti-
inflammatory effects in smokers with asthma in short
exploratory trials is therefore desirable. Extended nitric
oxide analysis aims to provide additional insights into
airway nitric oxide metabolism via simple mathematical
modelling7 and may overcome the impact of smoking on
1828 M. Spears et al.nitric oxide concentrations when measured at standard
flow rates. Cigarette smoking does not appear to affect
Calv in current smokers without respiratory disease
12,13
and elevated Calv levels have been detected in subjects
with COPD14,29 and asthma.16,29 This study is of impor-
tance as it examines nitric oxide parameters in a well
characterized group of subjects with stable asthma with
differing smoking histories, whilst simultaneously
exploring the impact of a strong anti-inflammatory treat-
ment. Our results demonstrate, for the first time, that
alveolar nitric oxide is not raised and that airway nitric
oxide flux is sensitive to oral dexamethasone in smokers
with asthma.
Prior to conducting this study our hypothesis was that
Calv levels would be elevated in smokers with asthma,
reflecting their untreated airway inflammation. This
hypothesis, if confirmed, would have provided an expla-
nation for smokers with asthma increased symptoms and
health care usage and an inflammatory endpoint to target
in this group. However this was not the case, even in the
presence of increased symptoms in our recruited subjects.
Another unexpected finding was the lack of clear change in
Calv in both groups in response to high dose corticosteroids,
which was surprising given the clear lung function response
in non-smokers with asthma. This leads us to question the
use of Calv as an exploratory endpoint in the study of airway
inflammation. Our conclusion is consistent with research
examining Calv in non-smoking adults with asthma.
30
However a study in a large group of Hispanic children
with asthma examining Calv
31 and previous research in
subjects with airway eosinophilia17 contradicts this
conclusion. On balance, the disparity between our results
and the published literature could reflect racial, age and
differences in the inflammatory processes at play in the
subjects recruited to previous research and ours. Smokers
with asthma are known to display altered airway inflam-
mation to non-smokers with asthma, with some heavy
smokers with asthma displaying sputum neutrophilia and, in
general, smokers with asthma display an absence of sputum
eosinophilia. In conclusion our results may differ from
previous research simply due to the lower levels of airway
eosinophilia in our group. Overall we feel that Calv does not
have the ideal characteristics to be employed as an
endpoint in smokers with asthma as it does not reflect the
airway inflammation that is undoubtedly present in this
group.
In contrast, J0aw, derived by both linear and non-linear
modelling, demonstrates sensitivity to oral corticosteroids
in both smokers and non-smokers with asthma with an
apparently equivalent relative change in both groups. The
reduction in J0aw in smokers with asthma following oral
corticosteroids is intriguing and suggests that J0aw may
provide sufficient responsiveness to detect anti-
inflammatory effects in a short exploratory study.
However an obvious question is why, in contrast to
measurement of FENO50, are we able to detect a statisti-
cally significant reduction in J0aw in response to cortico-
steroid, given previous research which demonstrates that
these indices are very strongly related31 and despite the
use of a strong anti-inflammatory treatment. The weak-
ening of the correlation between J0aw and FENO50 in
response to treatment in smokers with asthma, whilst stillstrong, suggests that J0aw is perhaps providing additional
information to FENO50 in this group. We would favour the
use of the linear derivation method to obtain results for Calv
and J0aw on pragmatic grounds as it requires fewer exha-
lations and therefore can be employed as part of a series of
tests in a study visit. However further characterisation will
be required regarding the relationship between rapid
changes in J0aw in smokers with asthma in the short term
clinical studies and improvements in traditional endpoints
employed in longer definitive clinical trials (similar to the
process that FENO50 has been undergoing).
32 This will be
crucial along with further work directed at understanding
the reproducibility of J0aw, its relationship with disease
severity and ability to predict disease behaviour.
The mechanisms responsible for reduced J0aw in smokers
with asthma are not clear at present but possible causes
include cigarette smoke induced consumption of nitric
oxide,33 competition for required substrates by other
inflammatory pathways activated by cigarette smoke34 and
reduced inducible nitric oxide synthase concentrations in
airway epithelial cells in response to smoking.35 Future
studies examining nitric oxide synthesis and reaction
products in the bronchial epithelium and submucosa in
smokers and non-smokers with asthma should be examined
in parallel with determination of Calv and J
0
aw to this end.
This study has a number of weaknesses that merit
discussion. The oral corticosteroid treatment was
unblinded and not placebo controlled. However previous
research has demonstrated that smokers with asthma
consistently display a reduced response to oral corticoste-
roids.5,6 The consistency of the presented findings and our
use of cortisol suppression as a measure of compliance lead
us to believe that our results are sound. Another issue that
must be discussed is that the recruited groups were not
perfectly matched, as the smokers with asthma had higher
median ACQ scores and inhaled corticosteroid doses
compared to non-smokers with asthma. Whilst these
differences are to be expected given previous research,27
could these differences and specifically the higher inhaled
corticosteroid doses used in the smokers with asthma be
responsible for the observed reduction in J0aw? We also did
not find any significant correlation between inhaled corti-
costeroid dose and J0aw in our subjects. However our small
sample size will have limited the ability to detect a weak
relationship and further examination of possible associa-
tions between inhaled corticosteroid dose and J0aw should
be undertaken in future studies.
In the first study to examine extended nitric oxide
analysis in a group of smokers with asthma, we demon-
strate that this group displays lower or similar levels of Calv
to non-smokers with asthma. J0aw levels are lower in
smokers with asthma and J0aw appears to display sufficient
sensitivity to provide a useful exploratory endpoint in
smokers with asthma and should undergo further
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